Radiopharmaceutical kit to prepare Copper-64 labelled porphyrin-lipid nanoparticles for radiotracer imaging studies in cancer patients
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07442-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Michael S Valic und 22 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada. Hauptthemen laut MEDLINE: Copper Radioisotopes, Porphyrins, Nanoparticles, Radiopharmaceuticals. Die Arbeit nennt 81 Literaturangaben. Gefördert von: Terry Fox Research Institute, Ontario Institute for Cancer Research, Princess Margaret Cancer Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: PORPHYSOMES (PS) are multifunctional porphyrin-lipid nanoparticles for fluorescence-guided photochemical tumour ablation and immune stimulation. PS can be radiolabelled with Copper-64 (64Cu-PS) to permit tracing of their whole-body distribution and uptake in tumours with nuclear imaging. Herein we characterised the physicochemical and radiochemical properties of PS and 64Cu-PS and evaluated their pharmacology and toxicology in rats and dogs. METHODS: 64Cu-PS labelling procedure was optimised and developed into a "one pot" kit format. The plasma pharmacokinetics (PK), tissue distribution, and single and repeat-dose toxicity of dose escalating PS was evaluated after intravenous injection in healthy Fisher 344 rats and Beagle dogs. Radiation dosimetry from single 64Cu-PS dose was estimated in humans. RESULTS: Kit prepared 64Cu-PS had high labelling yields and mean specific activities of 18.5 MBq/mg (11.4 GBq/mg max). The plasma PK of PS was linear between doses 0.5-15 mg/kg in both rats and dogs. Tissue distribution was primarily to the liver. The estimated effective dose from 64Cu-PS in humans was 38-47 µSv/MBq. Single doses of 32.6 mg/kg PS did not have detectable toxicities in rats. In dogs, mild transient infusion reactions were observed following single and repeat-doses of PS starting at ≥ 10 mg/kg PS. Doses up to 15 mg/kg PS were tolerated in dogs. CONCLUSIONS: The pharmacology and safety profiles of PS and 64Cu-PS in rats and dogs did not raise concerns regarding their use in humans. Radiolabelled 64Cu-PS will permit accurate imaging-based assessments of nanoparticle PK and tumour uptake in imaging studies in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT RM 5-354, Toronto, ON, M5G 1L7, Canada.
- Institute of Biomedical Engineering, Faculty of Applied Science and Engineering, University of Toronto, Toronto, Canada.
- Institute of Medical Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- Latner Thoracic Research Laboratories, University Health Network, Toronto, Canada.
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
- Guided Therapeutics Program, University Health Network, Toronto, Canada.
ORCID-Profile: Gang Zheng
Förderung
- Terry Fox Research Institute
- Ontario Institute for Cancer Research
- Princess Margaret Cancer Foundation
Zitieren
APA
Valic, M. S., Fisher, C. J., Zheng, M., Gregor, A. M., Jiang, W., Chan, C., Chan, H. H. L., El-Sayes, A., Zhang, C. J., Ye, T., Halim, M., Schimmer, P., Li, C., Bernards, N., Chu, A. C. K., Cai, Z., Chen, J., Irish, J. C., Yasufuku, K., …, & Zheng, G. (2025). Radiopharmaceutical kit to prepare Copper-64 labelled porphyrin-lipid nanoparticles for radiotracer imaging studies in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07442-5
Vancouver
Valic MS, Fisher CJ, Zheng M, Gregor AM, Jiang W, Chan C, et al. Radiopharmaceutical kit to prepare Copper-64 labelled porphyrin-lipid nanoparticles for radiotracer imaging studies in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07442-5
BibTeX
@article{Valic2025,
author = {Valic, Michael S and Fisher, Carl J and Zheng, Mark and Gregor, Alexander M and Jiang, Wenlei and Chan, Conrad and Chan, Harley H L and El-Sayes, Abdullah and Zhang, Chris J and Ye, Tina and Halim, Michael and Schimmer, Pamela and Li, Celina and Bernards, Nicholas and Chu, Arthur C K and Cai, Zhongli and Chen, Juan and Irish, Jonathan C and Yasufuku, Kazuhiro and Weersink, Robert and Reilly, Raymond M and Wilson, Brian C and Zheng, Gang},
title = {Radiopharmaceutical kit to prepare Copper-64 labelled porphyrin-lipid nanoparticles for radiotracer imaging studies in cancer patients},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07442-5}
}
EUVIMED